MoonLake Immunotherapeutics reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 0.450315 million. Basic loss per share from continuing operations was USD 0.12.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.85 USD | +2.23% | +2.77% | -32.36% |
05-07 | MoonLake Immunotherapeutics Q1 Net Loss Widens | MT |
05-07 | MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.36% | 2.57B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- MLTX Stock
- News MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023